Safety and Feasibility of Reversible Induction Strategy

September 11, 2021 updated by: diansan su, RenJi Hospital

Safety and Feasibility of Reversible Induction Strategy Supported by HFNC Combined With Specific Anesthetic

This study would explore the safety and feasibility of a reversible induction strategy for uncertain difficult airway. This reversible induction strategy would include high flow nasal canular oxygenation support, short-term effect anesthetic including Propofol and Remifentanil for sedation and analgesia and Sugammadex would be used for reverse the muscle relaxant.

Study Overview

Status

Recruiting

Conditions

Study Type

Observational

Enrollment (Anticipated)

20

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Shanghai
      • Shanghai, Shanghai, China, 200127
        • Recruiting
        • Ren Ji Hospital Affliated to School of Medicine, Shanghai Jiao Tong University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with an uncertain difficult airway, who will undergo a selective operation and need trachea intubtion.

Description

Inclusion Criteria:

  • >18 years old,<65 years old
  • Signed informed consent
  • Undergoing selective operation （ time of operation is over two hours）
  • ASA classification I-II
  • Mallampati classification 3-4
  • suspicious difficult airway, but the anesthetists decide to try to rapid induction

Exclusion Criteria:

  • Patients with several dysfunctions of liver, kidney or heart)
  • Patients with a full stomach or have other risk factors of reflux aspiration
  • Any medicine was taken before surgery, which might enhance or mitigate the effects of muscle relaxant
  • Infection of the mouth or nose
  • Allergy history of any medicine which would be used in this study
  • Pregnant and lactating women
  • Patients with neuromuscular disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Successful rate of reversion
Time Frame: From the beginning of induction to 15min later
From the beginning of induction to 15min later

Secondary Outcome Measures

Outcome Measure
Time Frame
TOFr 0.9 reversion time
Time Frame: From the beginning of induction to 15min later
From the beginning of induction to 15min later
BIS 80 reversion time
Time Frame: From the beginning of induction to 15min later
From the beginning of induction to 15min later
Tidal volume 6-8ml tidal volume 6-8ml/kg reversion time
Time Frame: From the beginning of induction to 15min later
From the beginning of induction to 15min later
consciousness reversion time
Time Frame: From the beginning of induction to 15min later
From the beginning of induction to 15min later

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

RenJi Hospital

Investigators

  • Study Director: diansan su, Renji Hospital, Shanghai Jiaotong University, Shanghai, China

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2021

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

June 15, 2020

First Submitted That Met QC Criteria

June 15, 2020

First Posted (Actual)

June 17, 2020

Study Record Updates

Last Update Posted (Actual)

September 14, 2021

Last Update Submitted That Met QC Criteria

September 11, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • RenjiH6502

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

IPD Plan Description

IPD is unavailable to other researchers

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gastric Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sri Lanka

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe